Clinical trials
Completed Thyroid Neoplasms trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
74 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 11 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 74 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Yonsei University | 7 |
| Cedars-Sinai Medical Center | 2 |
| Ling Zhiqiang | 2 |
| Mayo Clinic | 2 |
| Radboud University Medical Center | 2 |
| University of Alabama at Birmingham | 2 |
| University of Florida | 2 |
| Washington University School of Medicine | 2 |
| Ajou University School of Medicine | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thyroid Neoplasms | 74 |
| Thyroid Nodule | 15 |
| Breast Neoplasms | 9 |
| Head and Neck Neoplasms | 8 |
| Prostatic Neoplasms | 7 |
| Neoplasms | 6 |
| Colorectal Neoplasms | 5 |
| Kidney Neoplasms | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Sarcoma | 5 |
Trials
Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.